Stockholm, January 31, 2024 – Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced that Ahmed Mousa, Chief Executive Officer, will participate in the following investor conferences:

  • Guggenheim 6th Annual Biotechnology Conference
    Location: New York, NY.
    Fireside Chat Date and Time: February 7 at 2:30 PM ET/ 8:30 PM CET.
    Webcast Registration: Link
  • Oppenheimer 34th Annual Healthcare Life Sciences Conference
    Presentation Date and Time: February 13 at 10:40 AM ET / 4:40 PM CET.
    Webcast Registration: Link

For further information, please contact:
Ahmed Mousa, CEO, tel: +1 607 437 0235, ahmed.mousa@vicorepharma.com  
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com

This information was submitted for publication on January 31 at 08:00 CET.

About Vicore Pharma Holding AB (publ)
Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). C21 is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. Almee™ (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Using its unique expertise in ATRAG chemistry and biology, Vicore is further fueling its pipeline with several new therapies across additional potential indications. The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information visit www.vicorepharma.com.

Attachments
Vicore to Present at Upcoming Investor Conferences

© Modular Finance, source Nordic Press Releases